WO2023247738 - COMPOSITIONS AND METHODS FOR INHIBITING TRANSMEMBRANE SERINE PROTEASE 6 (TMPRSS6) EXPRESSION
National phase entry is expected:
Publication Number
WO/2023/247738
Publication Date
28.12.2023
International Application No.
PCT/EP2023/067070
International Filing Date
23.06.2023
Title **
[English]
COMPOSITIONS AND METHODS FOR INHIBITING TRANSMEMBRANE SERINE PROTEASE 6 (TMPRSS6) EXPRESSION
[French]
COMPOSITIONS ET PROCÉDÉS POUR INHIBER L'EXPRESSION DE LA SÉRINE PROTÉASE TRANSMEMBRANAIRE 6 (TMPRSS6)
Applicants **
NOVO NORDISK A/S
DICERNA PHARMACEUTICALS INC.
Inventors
BLOIS, Anna, Linda
PRIEST, Christina Marie
PARK, Jihye
DUDEK, Henryk
Priority Data
63/355,210
24.06.2022
US
22209113.4
23.11.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3135 | |
| EPO | Filing, Examination, Granting | 12362 | |
| Japan | Filing, Examination, Granting | 2172 | |
| South Korea | Filing, Examination, Granting | 2071 | |
| USA | Filing, Examination, Granting | 6840 |
Total:
26,580
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Oligonucleotides are provided herein that inhibit TMPRSS6 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with hepcidin deficiency or suppression. 5[French]
L'invention concerne des oligonucléotides qui inhibent l'expression de la TMPRSS6. L'invention concerne des compositions les comprenant et leurs utilisations, en particulier des utilisations liées au traitement de maladies, de troubles et/ou d'affections associés à l'expression de la TMPRSS6 .